Total Payments
$5,008
2024 Payments
$64.31
Companies
45
Transactions
207
Medicare Patients
2,068
Medicare Billing
$384,360
Payment Breakdown by Category
Food & Beverage$4,372 (87.3%)
Travel$420.82 (8.4%)
Education$214.95 (4.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,372 | 198 | 87.3% |
| Travel and Lodging | $420.82 | 2 | 8.4% |
| Education | $214.95 | 7 | 4.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,048 | 23 | $0 (2022) |
| GlaxoSmithKline, LLC. | $349.11 | 18 | $0 (2022) |
| Amgen Inc. | $329.64 | 12 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $308.69 | 18 | $0 (2022) |
| PFIZER INC. | $270.65 | 8 | $0 (2023) |
| EISAI INC. | $256.55 | 13 | $0 (2022) |
| Pharmacyclics LLC, an AbbVie Company | $227.33 | 11 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $204.99 | 10 | $0 (2022) |
| GENZYME CORPORATION | $187.75 | 8 | $0 (2022) |
| Seagen Inc. | $179.53 | 8 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $64.31 | 2 | Adaptive Biotechnologies Corporation ($37.35) |
| 2023 | $146.15 | 6 | PFIZER INC. ($45.14) |
| 2022 | $1,090 | 53 | GlaxoSmithKline, LLC. ($129.08) |
| 2021 | $1,831 | 92 | GlaxoSmithKline, LLC. ($220.03) |
| 2020 | $1,234 | 41 | Merck Sharp & Dohme Corporation ($745.30) |
| 2019 | $286.63 | 10 | Merck Sharp & Dohme Corporation ($124.51) |
| 2018 | $355.63 | 3 | PFIZER INC. ($134.59) |
All Payment Transactions
207 individual payment records from CMS Open Payments — Page 9 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/03/2019 | Seattle Genetics, Inc. | — | Food and Beverage | In-kind items and services | $23.32 | General |
| 08/27/2019 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $12.59 | General |
| Category: Oncology | ||||||
| 08/26/2019 | E.R. Squibb & Sons, L.L.C. | EMPLICITI (Biological) | Food and Beverage | Cash or cash equivalent | $11.25 | General |
| Category: Oncology | ||||||
| 03/05/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $105.00 | General |
| Category: ONCOLOGY | ||||||
| 06/21/2018 | SANOFI-AVENTIS U.S. LLC | JEVTANA (Drug) | Education | In-kind items and services | $99.95 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2018 | Amgen Inc. | XGEVA (Biological) | Food and Beverage | In-kind items and services | $121.09 | General |
| Category: Oncology | ||||||
| 04/19/2018 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $134.59 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 428 | 604 | $174,104 | $54,344 |
| 2022 | 10 | 654 | 1,253 | $469,393 | $147,977 |
| 2021 | 8 | 496 | 939 | $190,831 | $107,254 |
| 2020 | 8 | 490 | 828 | $155,584 | $74,784 |
Total Patients
2,068
Total Services
3,624
Medicare Billing
$384,360
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 153 | 255 | $83,107 | $21,759 | 26.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 81 | 116 | $22,224 | $9,167 | 41.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 53 | 70 | $19,234 | $8,107 | 42.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 29 | 42 | $16,165 | $4,848 | 30.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 31 | 31 | $12,926 | $4,450 | 34.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 47 | 48 | $11,131 | $2,887 | 25.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 23 | 31 | $5,819 | $1,939 | 33.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 11 | 11 | $3,497 | $1,188 | 34.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 234 | 635 | $219,075 | $68,688 | 31.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 112 | 262 | $127,070 | $41,465 | 32.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 70 | 70 | $41,370 | $12,481 | 30.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 76 | 93 | $22,785 | $6,937 | 30.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 33 | 33 | $14,751 | $4,504 | 30.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 40 | 44 | $15,180 | $4,503 | 29.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 30 | 37 | $9,065 | $2,861 | 31.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 30 | 45 | $8,325 | $2,670 | 32.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 18 | 23 | $6,118 | $2,006 | 32.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 11 | $5,654 | $1,862 | 32.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 189 | 459 | $89,343 | $50,257 | 56.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 82 | 168 | $42,312 | $25,967 | 61.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 60 | 60 | $22,260 | $11,520 | 51.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 84 | 108 | $14,239 | $7,863 | 55.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 35 | 83 | $10,458 | $5,042 | 48.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 20 | 20 | $5,920 | $2,807 | 47.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 15 | 27 | $4,563 | $2,387 | 52.3% |
About Dr. Manasa Vulchi, M.D
Dr. Manasa Vulchi, M.D is a Medical Oncology healthcare provider based in Rancho Mirage, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/15/2012. The National Provider Identifier (NPI) number assigned to this provider is 1760739296.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Manasa Vulchi, M.D has received a total of $5,008 in payments from pharmaceutical and medical device companies, with $64.31 received in 2024. These payments were reported across 207 transactions from 45 companies. The most common payment nature is "Food and Beverage" ($4,372).
As a Medicare-enrolled provider, Vulchi has provided services to 2,068 Medicare beneficiaries, totaling 3,624 services with total Medicare billing of $384,360. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Rancho Mirage, CA
- Active Since 08/15/2012
- Last Updated 06/19/2023
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1760739296
Products in Payments
- MK-7339 (Drug) $655.79
- KEYTRUDA (Biological) $358.90
- ZEJULA (Drug) $349.11
- IBRANCE (Drug) $243.97
- IMBRUVICA (Drug) $227.33
- Lenvima (Drug) $209.41
- JEVTANA (Drug) $197.48
- VERZENIO (Drug) $138.35
- XGEVA (Biological) $121.09
- LUMAKRAS (Drug) $119.18
- Enhertu (Drug) $115.28
- LYNPARZA (Drug) $99.85
- Pomalyst (Drug) $92.30
- PADCEV (Biological) $86.67
- TAGRISSO (Drug) $74.02
- SARCLISA (Biological) $65.71
- Trodelvy (Drug) $64.47
- Kyprolis (Drug) $61.38
- CALQUENCE (Drug) $58.24
- LIBTAYO (Biological) $54.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.